Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma.

Yamin Shu, Ying Tang,Yufeng Ding,Qilin Zhang

International immunopharmacology（2023）

引用 0|浏览3

暂无评分

摘要

Nivolumab as first-line treatment could gain more health benefits for advanced HCC compared with sorafenib, but was estimated not to be cost-effective at the commonly adopted WTP threshold of China.

查看译文

关键词

hepatocellular carcinoma,sorafenib,nivolumab,cost-effectiveness,first-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要